8-K: BioAffinity Technologies Reports Record Sales Growth and Outlines 2025 Expansion Plans

BioAffinity Technologies reports a record year in sales for its CyPath Lung test and outlines plans for expansion into new markets and clinical trials in 2025.

Summary

• BioAffinity Technologies hosted an investor webinar on December 19, 2024, to discuss their 2024 successes and plans for 2025.
• The company's CyPath Lung test, designed for early lung cancer detection, has seen a significant increase in sales, with a 1,700% increase through November 30th compared to the same period last year.
• Precision Pathology Laboratory Services, a wholly-owned subsidiary, is on track to report $9.4 million in revenue for 2024, representing a 20% growth in annualized revenue compared to 2023.
• The company plans to expand its sales efforts in 2025, targeting the Veterans Affairs (VA) and military markets, as well as key regions with existing physician interest.
• BioAffinity intends to initiate a clinical trial in 2025 to seek FDA clearance for CyPath Lung, with significant interest from VA medical centers.
• The company is also developing tests for other lung diseases, such as COPD and asthma, to complement their CyPath Lung offering.
• A study showed that using CyPath Lung could result in significant healthcare cost savings, potentially saving over $2,700 per Medicare patient and over $6,400 per privately insured patient.
• The company has a strong management team and board of directors with extensive experience in healthcare and finance.

Sentiment

Score: 8

Explanation: The document conveys a very positive outlook with strong sales growth, expansion plans, and promising clinical trial prospects. The management team's confidence and the potential for significant healthcare cost savings contribute to the high sentiment score.

Positives

• CyPath Lung has demonstrated high accuracy in detecting lung cancer with a 92% sensitivity and 87% specificity.
• The test is non-invasive, patient-friendly, and provides results to physicians within 2-3 days.
• The company has secured reimbursement for CyPath Lung and gained access to the federal healthcare system.
• The acquisition of Precision Pathology Services in 2023 has given the company control over lab operations and 100% of CyPath revenues.
• The company has a strong management team and board of directors with extensive experience.
• There is significant interest from VA medical centers in participating in the upcoming clinical trial.
• The company is expanding its sales team and marketing efforts.

Negatives

• The company is currently operating as a laboratory developed test (LDT), which is subject to specific regulations.
• The company is still in the process of seeking FDA clearance for CyPath Lung.
• The company is reliant on a single laboratory for the sale of CyPath Lung.

Risks

• The company's future success depends on the successful completion of the clinical trial and obtaining FDA clearance for CyPath Lung.
• Changes in regulations governing laboratory developed tests could impact the company's operations.
• The company faces competition in the lung cancer diagnostic market.
• The company's ability to expand into new markets and increase sales will depend on its marketing and sales efforts.
• The company's financial performance is dependent on the continued growth of CyPath Lung sales.

Future Outlook

BioAffinity Technologies plans to expand its sales efforts, initiate a clinical trial for FDA clearance, and develop new diagnostic tests for other lung diseases in 2025. The company expects continued record growth in sales.

Management Comments

• We are ready to execute on a plan in 2025 and beyond.
• We are ready to execute on a plan that can increase revenues, expand our market, advance new tests in our pipeline and conduct our pivotal trial.
• We remain focused on bringing shareholder value by helping physicians give their patients better diagnostics so they can take advantage of more targeted care that can lead to longer, healthier lives.
• CyPath Lung does not replace the tools a physician uses to find early cancer, it enhances and adds to the toolbox and can bring more clarity on next steps for both physicians and their patients.

Industry Context

The announcement highlights the growing importance of early cancer detection and the potential for non-invasive diagnostic tests like CyPath Lung. The company is positioning itself to capitalize on the increasing demand for lung cancer diagnostics, particularly in the context of a large at-risk population and the high cost of traditional diagnostic methods.

Comparison to Industry Standards

• The 92% sensitivity and 87% specificity of CyPath Lung are competitive with other early lung cancer detection methods.
• The potential cost savings of $2,700 per Medicare patient and $6,400 per privately insured patient are significant compared to traditional diagnostic pathways.
• The company's focus on a non-invasive, at-home collection method differentiates it from many other diagnostic tests.
• The company's expansion into the VA and military markets aligns with the trend of increasing healthcare access for veterans and active military personnel.
• The company's development of tests for COPD and asthma positions it to compete with companies such as Roche, Thermo Fisher Scientific, and Abbott in the broader respiratory diagnostics market.

Stakeholder Impact

• Shareholders can expect potential value creation through increased revenues and market expansion.
• Employees can expect growth opportunities as the company expands its operations.
• Patients can benefit from a non-invasive, accurate, and cost-effective diagnostic test for lung cancer.
• Physicians can benefit from a tool that enhances their ability to diagnose lung cancer early and improve patient outcomes.
• The healthcare system can benefit from significant cost savings through the use of CyPath Lung.

Next Steps

• Expand sales efforts into the VA and military markets.
• Initiate a clinical trial for FDA clearance of CyPath Lung.
• Develop diagnostic tests for COPD and asthma.
• Hire a marketing director to support sales growth.

Key Dates

Keywords

CyPath Lung, Lung Cancer, Early Detection, Diagnostics, Clinical Trial, FDA Clearance, COPD, Healthcare, Veterans Affairs, Sales Growth, Precision Pathology, Flow Cytometry, Medicare, Reimbursement